- Home
- ATOS vs ACRS Comparison
ATOS vs ACRS Comparison
Compare ATOS & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATOS
- ACRS
- Stock Information
- Founded
- ATOS 2009
- ACRS 2012
- Country
- ATOS United States
- ACRS United States
- Employees
- ATOS N/A
- ACRS N/A
- Industry
- ATOS Biotechnology: Pharmaceutical Preparations
- ACRS Biotechnology: Pharmaceutical Preparations
- Sector
- ATOS Health Care
- ACRS Health Care
- Exchange
- ATOS Nasdaq
- ACRS Nasdaq
- Market Cap
- ATOS 140.9M
- ACRS 132.0M
- IPO Year
- ATOS 2012
- ACRS 2015
- Fundamental
- Price
- ATOS $0.96
- ACRS $2.72
- Analyst Decision
- ATOS Strong Buy
- ACRS Strong Buy
- Analyst Count
- ATOS 3
- ACRS 5
- Target Price
- ATOS $7.00
- ACRS $8.75
- AVG Volume (30 Days)
- ATOS 952.6K
- ACRS 1.1M
- Earning Date
- ATOS 11-12-2024
- ACRS 11-06-2024
- Dividend Yield
- ATOS N/A
- ACRS N/A
- EPS Growth
- ATOS N/A
- ACRS N/A
- EPS
- ATOS N/A
- ACRS N/A
- Revenue
- ATOS N/A
- ACRS $27,079,000.00
- Revenue This Year
- ATOS N/A
- ACRS N/A
- Revenue Next Year
- ATOS N/A
- ACRS N/A
- P/E Ratio
- ATOS N/A
- ACRS N/A
- Revenue Growth
- ATOS N/A
- ACRS 26.35
- 52 Week Low
- ATOS $0.73
- ACRS $0.86
- 52 Week High
- ATOS $2.31
- ACRS $5.17
- Technical
- Relative Strength Index (RSI)
- ATOS 24.57
- ACRS 41.17
- Support Level
- ATOS $1.17
- ACRS $2.91
- Resistance Level
- ATOS $1.30
- ACRS $3.29
- Average True Range (ATR)
- ATOS 0.08
- ACRS 0.29
- MACD
- ATOS -0.02
- ACRS -0.18
- Stochastic Oscillator
- ATOS 1.09
- ACRS 0.75
About ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary innovative medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases. The contract research segment earns revenue from the provision of laboratory services. The majority of its revenue comes from the contract research segment, which provides laboratory services. Its drug candidates under development are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138 is an ITJ Inhibitor; and ATI-1777.